OverviewSuggest Edit

OncoSenX is a late stage pre-clinical cancer company which focuses on genetic information to discover the next generation of cancer therapy. It targets solid tumors based on transcriptional activity using a lipid nanoparticle and plasmid DNA. The company offers a less invasive, more precise intervention approach.


Latest Updates

Employees (est.) (Jan 2022)12(+10%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at OncoSenX

Matthew Scholz

Matthew Scholz

Chief Executive Officer
John D. Lewis

John D. Lewis

Chief Science Officer
Gary C. Hudson

Gary C. Hudson

Board Member
Eric Garcia

Eric Garcia

Chief Operating Officer
Stephen Hilbert

Stephen Hilbert

Chief Business Officer
Show more

OncoSenX Financials and Metrics

Summary Metrics

OncoSenX total Funding

$3 m

OncoSenX latest funding size

$3 m

Time since last funding

3 years ago
OncoSenX's latest funding round in July 2019 was reported to be $3 m. In total, OncoSenX has raised $3 m
Show all financial metrics

OncoSenX Online and Social Media Presence

Embed Graph

OncoSenX Frequently Asked Questions

  • Who are OncoSenX key executives?

    OncoSenX's key executives are Matthew Scholz, John D. Lewis and Gary C. Hudson.

  • How many employees does OncoSenX have?

    OncoSenX has 12 employees.

  • Who are OncoSenX competitors?

    Competitors of OncoSenX include Strata Oncology, LXRepair and Serotiny.